In‐flight glycaemic control using automated insulin delivery systems: A within‐subject comparative pilot study
Authors:
- Renald MeçaniRMRenald Meçani
- Silvia BastaSBSilvia Basta
- Petra M. BaumannPBPetra M. Baumann
- Monika CiglerMCMonika Cigler
- Omaima el HakouniOHOmaima el Hakouni
- Daniel A. HochfellnerDHDaniel A. Hochfellner
- Fariba Shojaee‐MoradieFSFariba Shojaee‐Moradie
- Ka Siu FanKFKa Siu Fan
- Dietrich TewsDTDietrich Tews
- Thomas R. PieberTPThomas R. Pieber
- David Russell‐JonesDRDavid Russell‐Jones
- Chantal MathieuCMChantal Mathieu
Open Access
- 22 December 2025
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 2159-2165
Abstract
Background: Automated insulin delivery systems (AID) are increasingly used by people living with type 1 diabetes, but their functionality during air travel remains insufficiently studied. Some concerns have arisen regarding safety using AID systems under flight conditions, particularly related to potential insulin delivery errors induced by cabin pressure changes. Methods: This study assessed the safety and efficacy commercial AIDs in 20 adults with type 1 diabetes (age: 37.9 ± 12.8 years, HbA1c: 52.3 ± 4.9 mmol/mol, TIR: 74 ± 9.8%, diabetes duration: 19.25 ± 10.6 years) during mid‐haul commercial flights and matched ground‐based conditions (MiniMed780G; Omnipod 5; Control‐IQ; and CamAPS FX with YpsoPump, n = 5 per system). Outcomes included time in range (TIR, 3.9–10.0 mmol/L), time in tight range (TITR, 3.9–7.8 mmol/L), time above range 1 (TAR1, 10.1–13.9 mmol/L), time above range 2 (TAR2, >13.9 mmol/L), time below range 1 (TBR1, 3.0–3.8 mmol/L), time below range 2 (TBR2, <3.0 mmol/L), and total daily insulin doses. Results: Overall TIR was 88.2 ± 13.5% in‐flight versus 82.1 ± 17.7% on‐ground. The mean difference in TIR was 4.6%, (95% CI: −5.0‐ 14.2). Other overall metrics (in‐flight versus on‐ground) were: TITR = 67.7 ± 19.4% vs. 64.2 ± 18.1%, TAR = 7.1 ± 10.5% vs. 12.0 ± 13.8% and TBR = 4.7 ± 7.2% vs. 5.9 ± 15.7%. Insulin delivery was slightly increased in‐flight (25.4 ± 17.6 IU vs. 18.7 ± 11.6 IU), driven by bolus dosing (17.8 ± 13.3 IU vs. 11.9 ± 6.6 IU). No episodes of level 2 hypoglycaemia, diabetic ketoacidosis, or device failure occurred. Conclusions: AID systems maintained robust glycaemic control and safety during commercial flights, comparable to ground‐based conditions. These data support the feasibility of in‐flight AIDs use and provide a basis for future regulatory and clinical practice updates. Larger, multicenter studies are needed to generalize findings.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy and Safety of Automated Insulin Delivery Systems in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-AnalysisDiabetes & Metabolism Journal, 2025
- The Feasibility of an Experimental Hypobaric Simulation to Evaluate the Safety of Closed-Loop Insulin Delivery Systems in Flight-Related Atmospheric Pressure ChangesDiabetes Technology & Therapeutics, 2025
- Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023Life, 2023
- Medical Certification of Pilots Through the Insulin-Treated Diabetes Mellitus Protocol at the FAAAerospace Medicine and Human Performance, 2022
- Pilots flying with insulin‐treated diabetesDiabetes, Obesity and Metabolism, 2021
- Aircraft pilot licence and diabetesDiabetes Research and Clinical Practice, 2020
- Continuous Glucose Monitoring for In-Flight Measurement of Glucose Levels of Insulin-Treated PilotsAerospace Medicine and Human Performance, 2019
- Aviation Medicine: Illness and Limitations for Flying2016
- Driving with Diabetes: Precaution, Not Prohibition, is the Proper ApproachJournal of Diabetes Science and Technology, 2013
- Fighting discriminationDiabetes Research and Clinical Practice, 2012